# OnCo record stylus-medicine (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/stylus-medicine/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "stylus-medicine" ;
  schema:name "Stylus Medicine"@en ;
  schema:description "Stylus Medicine is building a way to add a CAR gene to T cells while they are still in the body, using a fat-based particle that carries an enzyme able to insert a large piece of DNA. Its first goal is CAR-T therapy without a manufacturing step; it was preclinical when it launched in 2025."@en ;
  schema:url <https://onco.cc/companies/stylus-medicine/>, <https://www.stylusmedicine.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.stylusmedicine.com/>, <https://sparkmed.stanford.edu/stylus-medicine-emerges-from-stealth-to-develop-in-vivo-genetic-medicines>, <https://www.pharmaceutical-technology.com/news/stylus-medicine-launches-with-85m-to-advance-in-vivo-gene-editing> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/in-vivo-car-t/> .